<DOC>
	<DOC>NCT00315445</DOC>
	<brief_summary>The objective of this study is to assess the safety of the buprenorphine transdermal system (5, 10, and 20) in comparison to placebo transdermal system and immediate release oxycodone/ acetaminophen in subjects with chronic back pain. The double-blind treatment intervention duration is 84 days during which time supplemental analgesic medication (non-steroidal anti-inflammatory drugs) will be allowed for all subjects in addition to study drug.</brief_summary>
	<brief_title>The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.</brief_title>
	<detailed_description>Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>clinical evidence of stable, chronic (&gt;2 months) back pain related to intervertebral disc disease, nerve root entrapment, spondylolithesis, and osteoarthritis or other, similar nonmalignant conditions. unacceptable pain control despite currently taking a nonsteroidal antiinflammatory drug considered at a therapeutic and/or tolerated dose or, subjects currently taking &lt;/=2 shortacting opioid doses per day, or subjects taking 312 shortacting opioid doses per day. receiving opioids at an average daily dose of &gt;90 mg of oral morphine equivalents or receiving more than 12 tablets per day of shortacting opioidcontaining products. scheduled to have surgery (including dental) involving the use of preoperative or postoperative analgesics or anesthetics during the study period. Other protocolspecific exclusion/inclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>chronic back pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
</DOC>